Long-Term Results of Guided Tissue Regeneration Therapy With Non-Resorbable and Bioabsorbable Barriers. III. Class II Furcations After 10 Years

• Autores: Peter Eickholz, Bernadette Pretzl, Rolf Holle, Ti-Sun Kim
• Localización: Journal of periodontology, ISSN 0022-3492, Vol. 77, Nº. 1, 2006, págs. 88-94
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Correspondence: Dr. Peter Eickholz, Poliklinik für Parodontologie, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany. E-mail: eickholz@med.uni-frankfurt.de.

    Background: The aim of this 10-year follow-up was to evaluate the long-term results after guided tissue regeneration (GTR) therapy of Class II furcation defects using non-resorbable and bioabsorbable barriers clinically.

    Methods: In nine patients with advanced periodontitis, nine pairs of contralateral Class II furcation defects were treated. Within each patient, one defect received a non-resorbable expanded polytetrafluoroethylene barrier (ePTFE; C) and the other a bioabsorbable (polyglactin 910; T) barrier by random assignment. At baseline and 12 and 120 ± 6 months after surgery, clinical parameters were obtained.

    Results: Twelve and 120 months after GTR therapy, statistically significant (P <0.05) horizontal clinical attachment level (CAL-H) gain was observed in both groups (C12: 1.9 ± 0.5 mm; C120: 1.1 ± 1.3 mm; T12: 1.9 ± 0.8 mm; T120: 1.7 ± 1.4 mm). However, one patient with furcations that had been assessed as Class I 12 months after GTR therapy had lost two teeth after 10 years, and another patient had lost more than 2 mm CAL-H at one furcation from 12 to 120 ± 6 months post-surgery 10 years after implantation of an ePTFE barrier. Horizontal bone sounding revealed similar bone gain in both groups 120 ± 6 months post-surgery (C120: 0.8 ± 1.0 mm; T120: 1.1 ± 1.1 mm).

    Conclusions: CAL-H gain achieved after GTR therapy in Class II furcations was stable after 10 years in 15 of 18 defects (83%). The study failed to show a statistically significant difference in stability of CAL-H gain between group C and T 10 years after GTR therapy.